Explain this page
Arphra AIPlain-English read on Eli Lilly and Company’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$2,474.31
+112.88% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
2bull15bear
±5% threshold
Analyst PT consensus: $1,266.17 (+8.93%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.28% | +1.69% | +20.20% | +16.25% | +15.15% | +8.15% | +43.74% | +161.01% | +418.68% | +1473.68% | +41263.70% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$23.84M
10 txns
Net flow
−$23.84M
Aftermarket
LiveLast trade
$1162.28
920 sh
Bid
$1152.63
40 sh
Ask
$1162.60
120 sh
Spread
$9.970
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $19.8B | $7.4B | $8.26 |
| Q4 Dec 2025 | $19.29B | $6.64B | $7.39 |
| Q3 Sep 2025 | $17.6B | $5.58B | $6.21 |
| Q2 Jun 2025 | $15.56B | $5.66B | $6.29 |
| Q1 Mar 2025 | $12.73B | $2.76B | $3.06 |
| Q4 Dec 2024 | $13.53B | $4.41B | $4.88 |
Sector & industry today
LiveSectors
- Utilities+1.56%
- Technology+0.78%
- Industrials+0.48%
- Consumer Cyclical+0.42%
- Basic Materials+0.24%
- Healthcare+0.22%
- Consumer Defensive+0.01%
- Real Estate-0.11%
- Energy-0.47%
- Financial Services-0.67%
- Communication Services-0.70%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.82%
- Software - Infrastructure-7.18%
- Manufacturing - Metal Fabrication+1.83%
- Travel Services+1.59%
- Trucking+1.53%
- Leisure+1.47%
- Medical - Equipment & Services+1.42%
- Silver+1.34%
- Luxury Goods+1.31%
- Education & Training Services-1.09%
- Medical - Healthcare Plans-1.06%
- Computer Hardware+1.02%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$1,266.17
+8.93% upside
Low
$1,119.00
Median
$1,270.00
High
$1,400.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Carezacks.com·Jun 10, 2026
- Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagonreuters.com·Jun 10, 2026
- Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitisprnewswire.com·Jun 09, 2026
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitisprnewswire.com·Jun 09, 2026
- Is It Too Late To Buy The Rally In Eli Lilly Stock?forbes.com·Jun 09, 2026
- Prediction: Eli Lilly Will Trade at This Price in a Year247wallst.com·Jun 09, 2026
- Lilly Makes a New Alzheimer's Pipeline Movegurufocus.com·Jun 09, 2026
Recent analyst activity
DB- Jun 09, 2026GradeBuy → BuyEli Lilly price target raised to $1,350 from $1,330 at JefferiesJefferies
- Jun 09, 2026PT$1350.00Eli Lilly price target raised to $1,350 from $1,330 at JefferiesJefferies
- Jun 08, 2026GradeOutperform → OutperformBernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)Bernstein
- Jun 05, 2026GradeOverweight → OverweightMorgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'Morgan Stanley
Peers
Total assets
$112.48B
Total debt
$42.5B
Cash & equiv
$7.16B
Operating CF
$16.81B
Free cash flow
$8.97B
Buybacks
-$4.11B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 2,208 | $2.2M | May 06, 2026 |
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 13,620 | $13.55M | May 06, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,070 | $1.16M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,322 | $1.45M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 895 | $971.17K | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 930 | $1.01M | Jan 07, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $65.18B | $29.7B | $20.64B | $22.95 | +31.66% |
| FY 2024 | $45.04B | $17.5B | $10.59B | $11.71 | +23.51% |
| FY 2023 | $34.12B | $10.79B | $5.24B | $5.80 | +15.36% |
| FY 2022 | $28.54B | $8.65B | $6.24B | $6.57 | +21.88% |
| FY 2021 | $28.32B | $7.93B | $5.58B | $5.85 | +19.71% |